Specialty growth masked by fourth consecutive quarterly loss

Specialty chemicals ₹427 Cr (38% of consolidated revenue); standalone EBITDA only ₹7 Cr amid ₹176 Cr group loss

Q1 spread was negative due to ₹1000+/ton VCM inventory vs ₹700-750 realization; replacement spreads only reach stated level post-August

Confirmed: Paste PVC $200 upwards vs Suspension; standalone facility showed better margins due to higher realization

VCM currently $700 delivered vs $1000+ booked in March; Middle East easing and plant utilization at 70-80% support thesis

CMCD 21% volume growth noted; but company-wide net loss of ₹176 Cr and refusal to guide on profitability timing undermines confidence claim

Current ₹160/ton spread cited; ₹30 additional needed for PAT positive; confirms management's math but reveals thin runway to profitability

CMCD 21% volume growth, 14 molecules now commercial (vs implied lower prior quarter); management claims recovery underway post-slowdown. Order book described as 'healthy' but no value disclosed.

Q1 was deeply loss-making; recovery now expected Q3 (not Q2), dependent on VCM price $700 (currently true but subject to geopolitical swings). Prior call did not explicitly guide Q1 loss magnitude.

R32 commercial production started May 2026 from swing plant; full capacity online by fiscal year-end. Management declined to guide revenue/margin contribution, citing 'too early' — flag for underperformance risk.

CFO cited 'conserved cash' and 'sufficient liquidity' to service ₹235 Cr annual interest without guidance on cash runway or refinance needs. Against prior call, no specific debt reduction targets mentioned.

High-cost VCM inventory $1000+ booked in March; will consume by July-August. Replacement VCM now $700; PVC $900+; spread $150-160 net of taxes available.

Paste: court order on provisional bond is deterrent to low-price dumping; pricing will adjust normatively. Suspension: pursuing ADD on quarterly basis if data supports. Focus is level playing field, technically competitive with global players.

On track on ₹1000 Cr target; pickup is molecules commercialized ramping as expected; expect trend to continue coming quarters.

50 molecules in pipeline, 14 commercial, anticipate more commercialization coming months. ₹1000 Cr mostly agchem, rest reflective of future diversification work.

Cannot comment due to confidentiality; assure multiple customers, multiple innovators, multiple products. Concentrated mostly in agchem.

Deferral timing-driven (FY to calendar year). Agchem overall subdued, reviving, but significant competition from Chinese generics. Our ramp-up molecules on healthy positive trend, delays quarter-to-quarter manageable.

All capacities online by end of this fiscal as per plan. Go-to-market both domestic and international; active discussions with partners; partnerships tied up by capacity online.

Excluding Phase 3 just commissioned, 60-70% utilization on older assets; multipurpose blocks can't sustain 95-100%. Reaching stage where optimizing costs to industry-level returns this year.

Conserved cash over years; current accruals will cover debt servicing obligations; sufficient liquidity in system.

Negative spread; average VCM landing $1000+ per ton vs realization ₹700-750 per ton.

EBITDA neutral needs ₹120-130 per ton; PBT positive another ₹20-30 spread.

Entire onerous contracts reversed; high-cost inventory again in Q1; net provision ₹90 Cr (CCVL), ₹30 Cr (Chemplast) for reversal this quarter.

Normal formula-based pricing; April-May 2-3 months anomaly. Market price not fixed, PVC/VCM spread normally 80-150 range; this was aberration. Spot buying would be worse.

4 triggers: Suspension PVC customs duty + MIP, Paste PVC duty back + court order, CMCD strong quarter + healthy order book, R32 profitable by Q4. All put together, confident business turns around and moves towards positive.

Full ramp-up Q4 FY27 and Q1 FY28; see healthy margin contribution but too early for forward guidance. Per plan, one of profitable segments.

Won't give exact number. Positive triggers happened. Worst is over; Q3 should see reasonable performance. Specialty side especially positive.

Yes, various pharma projects ongoing; most pipeline development stage; some commercial late this year or early next FY.

Contingent on VCM $700 sustained (vs global commodity risk), customs duty/MIP stability. CMCD upside unquantified.

Current spreads at ₹160; thin buffer. Dependent on commodity price stability and no geopolitical shocks. Paste PVC spread ₹200+ guidance supported.

Vague; no specific margin % or ROCE target. Implies gradual contribution margin expansion on ramp-up molecules.

Stated 'per plan, not changing'; October 2026 date cited for Paste PVC project. R32 committed by year-end FY27.

Current ₹160/ton spread only achieves EBITDA breakeven. Q1 saw negative spreads due to $1000+ VCM inventory vs $700-750 realization. Global geopolitical shocks (e.g., Middle East conflict March 2026) drove VCM spike; repeat would wipe margin gains.

₹90 Cr (CCVL) and ₹30 Cr (Chemplast) NRV provisions reversing in Q2 FY27, but management withheld details on 1-2 additional loss-making contracts mentioned. Formula-based pricing locked when global prices spike, as happened March-May 2026.

₹235 Cr annual interest obligation against ₹176 Cr net loss in Q1 and negative FCF due to growth capex (Paste PVC debottlenecking, R32 capacity, CMCD Phase 3-4). CFO stated sufficient 'conserved cash', but no runway disclosure. Risk: if profitability inflection delays beyond Q3, refinance pressure rises.

50-molecule pipeline; 14 commercial; ₹1000 Cr target ~3 years out. Most pipeline molecules in development stage; agchem market subdued with Chinese generic competition. Management withheld customer/product concentration data due to confidentiality, obscuring customer attrition risk. Deferral in agchem noted last quarter; confirmed 'reviving' but still competitive.

Fire incident July 17, 2026 at Karaikal PVC plant; manual shutdown, no injuries, contained in 15 minutes. Management stated corrective actions underway, timeline for restart not disclosed. Risk: production disruption, regulatory inspection delays, liability tail unquantified.